GSA Capital Partners’s AstraZeneca AZN Stock Holding History

GSA Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,992	Closed	-$3.63M	–	1650
2025 Q2	$3.63M	Buy	+25,992	New	+$3.64M	0.25%	30
2025 Q1	–	Sell	-1,976	Closed	-$259K	–	1646
2024 Q4	$259K	Buy	+1,976	New	+$277K	0.02%	1286
2024 Q3	–	Sell	-2,436	Closed	-$380K	–	1591
2024 Q2	$380K	Buy	+2,436	New	+$367K	0.03%	1138
2022 Q2	–	Sell	-2,214	Closed	-$294K	–	1400
2022 Q1	$294K	Buy	+2,214	New	+$266K	0.04%	905
2019 Q4	–	Sell	-4,225	Closed	-$377K	–	1426
2019 Q3	$377K	Buy	+4,225	New	+$366K	0.05%	731
2016 Q2	–	Sell	-8,035	Closed	-$453K	–	1733
2016 Q1	$453K	Buy	+8,035	New	+$483K	0.03%	1081
2014 Q2	–	Sell	-5,343	Closed	-$347K	–	1799
2014 Q1	$347K	Buy	+5,343	New	+$345K	0.02%	1022
2013 Q3	–	Sell	-4,964	Closed	-$235K	–	1553
2013 Q2	$235K	Buy	+4,964	New	+$253K	0.03%	1004

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's AZN Position: Q3 2025 in Review

GSA Capital Partners sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 25,992 shares — an estimated $3.63M sold.

GSA Capital Partners first reported a position in AZN in Q2 2013 and held it in 8 quarters. The position peaked at $3.63M in Q2 2025. 1,289 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

GSA Capital Partners reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
GSA Capital Partners sold 25,992 AstraZeneca shares in Q3 2025, an estimated $3.63M.
GSA Capital Partners first reported a position in AstraZeneca in Q2 2013 and held it in 8 quarters.
GSA Capital Partners's AstraZeneca position peaked at $3.63M in Q2 2025.
1,289 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.